High Point, North Carolina-based vTv Therapeutics announced positive results from a mechanistic study of TTP399 in type 1 diabetes patients. 

The U.S. Food and Drug Administration classified the recall of Abbott Laboratories’ CentriMag blood pumping system, following the death of a patient, as Class 1 or the most serious type of recall.

For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.

The U.S. FDA approved for marketing DreaMed Diabetes’ Advisor Pro software to help manage diabetes treatment.

DURECT Corporation announced that its Posimir (SABER – Bupivacaine) for post-surgical pain failed a Phase III clinical trial.

Johnson & Johnson’s diabetes care unit will shut down its business in the United States and Canada amid increased competition and after failing to find a buyer.

Medtronic Plc said it signed an agreement with health insurer Aetna Inc. under which payment for its insulin pump systems will be tied to how well diabetes patients fare after switching from multiple daily insulin injections.

Abbott Laboratories is recalling for more than 28,000 of its HeartMate II blood pumps after 26 patients died after attempting to exchange controllers while away from the hospital.

Medtronic Plc won U.S. approval for an “artificial pancreas” that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day.

Intarcia Therapeutics, with an enviable cash pile to fund development of its matchstick-size implantable drug-delivery pump for diabetes, is happy to sit out the current initial public offering (IPO) boom. The Boston-based group clinched a royalty-based financing deal in April valuing the company at $5.5 billion, more than any other unlisted emerging biotechnology business in […]